Cite

HARVARD Citation

    Imaji, M. et al. (2023). Safety and efficacy of osimertinib rechallenge or continuation after pneumonitis: A multicentre retrospective cohort study. European journal of cancer. pp. 15-24. [Online]. 
  
Back to record